Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Distinct DNA Methylation Patterns Associated with Myalgic Encephalomyelitis

Lara C. Pullen, PhD  |  Issue: October 2018  |  August 28, 2018

DNA methylation plays an important role in the interplay between environment and gene expression. Because differential methylation of promoters can affect the expression of corresponding genes, methylation patterns may provide insight into the pathophysiology of multisystem complex diseases, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Researchers are particularly interested in methylation patterns in ME/CFS patients because transcriptional profiling studies in this patient population have revealed perturbations in T cell and B cell activation, as well as dysregulation in interleukins and interferons.

A recent study by Malav S. Trivedi, PhD, of Nova Southeastern University, Fort Lauderdale, Fla., and colleagues has explored the genome-wide epigenetic changes associated with ME/CFS. The investigators used advanced Infinium MethylationEPIC microarrays that covered approximately 850,000 CpG sites in two geographically distant cohorts of ME/CFS cases, as well as matched controls. Their results were published July 23 in PLOS One.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We identified differentially methylated CpG sites and promoters in PBMCs [peripheral blood mononuclear cells] of ME/CFS cases compared with controls in cohorts from two distant geographic locations,” write the authors in their discussion. “Association of hypomethylation of DMPs [differentially methylated promoters] with immune regulatory pathways is in agreement with previous studies. Those previous studies found immune cell regulation as the largest coordinated enrichment of differentially methylated pathways and reported genomic DNA hypomethylation of genes in immune pathways from PBMCs isolated from ME/CFS cases and also in CD4+ T cells from ME/CFS cases.”

Although the investigators found global DNA methylation levels of ME/CFS patients were like those of controls, they identified 17,296 differentially methylated CpG sites in 6,368 genes that included both regulatory elements and coding regions of genes. When they looked specifically at DNA methylation in promoter regions, they found 307 differentially methylated promoters, including hypomethylation of promoters of genes related to RNA binding proteins, homeobox and plant homeodomain finger proteins. When the researchers performed an ingenuity pathway analysis, they found the genes associated with differentially methylated promoters participated in at least 15 different pathways, most of which were related to cell signaling and had a strong immune component. In particular, the team documented hypomethylation of the IL21R gene promoter, a finding that suggests increased expression of the IL21 receptor.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It is noteworthy to mention that it is still inconclusive from previous studies or our current study, whether the significant epigenetic modifications found to associate with ME/CFS indicate a compensatory homeostatic mechanism or result from an adaptive immune response towards environmental inducers,” acknowledge the authors. “However, these results indicate DNA methylation constitutes a potential gene regulatory mechanism capable of mediating long-term changes in ME/CFS cases, as previously noted by other authors.”

Page: 1 2 | Single Page
Share: 

Filed under:Conditions Tagged with:chronic fatigue syndromeDNA Methylationmyalgic encephalomyelitis

Related Articles

    A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome

    September 26, 2017

    A session at the FOCIS 2017 meeting examined the current challenges and understanding of chronic fatigue syndrome, also called myalgic encephalomyelitis, in the hope of stimulating new approaches to deciphering the disease’s mechanistic and immunological underpinnings…

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Redefined

    June 15, 2015

    A report from the Institute of Medicine that gives new diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and recommends a new name for the disorder received mixed reviews from rheumatologists and other physicians.1 “Diagnosing ME/CFS often is a challenge … the new diagnostic criteria will make it easier for clinicians to recognize and accurately…

    Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

    October 17, 2017

    CHICAGO—Joseph Breen, PhD, program officer at the National Institutes of Health in Bethesda, Md., opened the chronic fatigue syndrome (CFS) session at the Federation of Clinical Immunology Societies (FOCIS) 2017 meeting by asking presenters to describe the current state of the science to the key immunology stakeholders gathered in the room. The hope was that…

    DNA Methylation Profiles May Shed Light on the Evolution of Arthritis in Patients

    April 26, 2022

    A study found DNA methylation profiling may predict if a patient will progress from a diagnosis of undifferentiated arthritis to that of rheumatoid arthritis (RA). The findings also suggest a pre-established epigenetic signature exists in patients diagnosed with undifferentiated arthritis that evolves into RA.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences